Background Osteoporosis in transplanted patients is a well-documented event, and shows a multifactorial etiology. Intervention and prevention in these patients could be related to a secondary osteoporotic effect decreasing (as a reduced fracture incidence), as well as a reduced sanitary cost associated to fracture treatment and intervention.
Objectives The identification of osteoporotic fracture incidence reduction in hepatic transplanted patients with preventive osteoporotic treatment.
Methods We considered 142 hepatic transplanted patients (that had undergone surgery at the reference hospital) immediately after the transplantation and at one-year after monitoring. Demographic and clinical data about symptomatic fractures and radiological fracture diagnosis where collected. All patients were administered 1000 mg Ca daily, 5600 IU vitD weekly and 200 IU calcitonin nasally during the first three months followed by oral Bophosphonates (as is described on bibliography).
Results Our samples series consists of 76% of men and 24% of women. The average transplant age is 53.61 years, and no significant variations of this variable in both sexes were observed.
The clinical diagnosis on which the transplant is based is shown in the following table:
Mainly, transplants are due to VHC and chronic enolism. In 23 patients basal fractures were observed (all vertebral), and after treatment 9 new fractures (8 vertebrals and 1 in ankle) were observed. In this way, fracture rate decreases from 13.38% at trasplant to 7.9% at annual monitoring, with a relative decrease of the fracture risk in 40.95%, even in HCV patients a decrease from 17.34% to 5.79% 1 year later was observed (relative risk of decrease 66.6%).
Conclusions Preventive osteoporosis treatment in hepatic transplanted patients leads to a decreasing on osteoporotic fracture risk, as is shown on control results and the monitoring of clinical results in these patients. Thus, it is possible to reach an osteoporotic post-transplant event decrease, as well as the decrease of the sanitary derived-cost.
Disclosure of Interest None Declared